Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
[6] It is worth noting that AOD 9604 does not appear to affect natural hGH production and does not appear to act as a growth hormone secretagogue
It is classified as a triple incretin receptor agonist, meaning it simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Clinical Context & Research Overview Important: Peptide therapy for metabolic support should be discussed with a licensed clinician
Because NAD
J3490 requires an invoice attachment and is likely to be denied or pended
Always consult a qualified healthcare professional before starting, stopping, or combining any medications
